FSHD1与FSHD2构成疾病连续谱
这项全国多中心队列研究纳入103例面肩肱型肌营养不良症(FSHD)患者,比较FSHD1与FSHD2的遗传和表观遗传特征与临床严重程度。研究发现携带9-10个D4Z4重复单元且伴致病性SMCHD1变异的患者同时具有两型特征,且SMCHD1突变携带者临床评分显著差于上端FSHD1等位基因患者,提示两型构成疾病连续谱,原有重复大小阈值需重新考量。
要点
- FSHD1与FSHD2在9-10个D4Z4重复单元范围存在重叠,构成疾病连续谱。
- 所有临床受累的SMCHD1突变携带者均携带9-16个D4Z4重复单元及4qA许可单倍型。
- SMCHD1突变携带者临床严重程度显著高于上端FSHD1等位基因(8-10 RU)患者。
核心结论
- FSHD1与FSHD2在9-10个D4Z4重复单元范围重叠,提示两型构成疾病连续谱。
- 既往FSHD1(1-10 RU)与FSHD2(11-20 RU)的重复大小阈值需重新考量。
研究设计与样本
- 全国多中心队列研究,纳入103例患者(54男49女),其中FSHD1 64例、FSHD2 20例。
- 采用手动肌力测试总分、Brooke评分、Vignos评分、临床严重程度评分(CSS)及年龄校正CSS评估运动力量、运动功能和疾病严重程度。
- 将临床评分与遗传参数(D4Z4重复大小和单倍型、SMCHD1变异状态)及表观遗传参数(D4Z4甲基化)进行关联分析。
主要发现
- 7例患者同时具有FSHD1和FSHD2的遗传与表观遗传特征,均携带9-10个D4Z4重复单元及致病性SMCHD1变异。
- 所有临床受累的SMCHD1突变携带者均携带9-16个D4Z4重复单元,位于疾病许可的4qA单倍型上。
- 与上端FSHD1等位基因(8-10 RU)患者相比,上述SMCHD1突变携带者在所有临床量表上均显著更严重。
关键数值与推荐
- FSHD1既往重复大小阈值为1-10 RU,FSHD2为11-20 RU。
- 上端FSHD1等位基因定义为8-10个D4Z4重复单元。
- 临床受累SMCHD1突变携带者的D4Z4重复范围为9-16 RU。
临床怎么用
- 对9-10个D4Z4重复单元且伴SMCHD1变异的患者应识别为FSHD1与FSHD2重叠表型。
- 评估FSHD患者时需同时考虑D4Z4重复大小、SMCHD1变异状态及4qA单倍型。
- 临床严重程度评估可结合手动肌力测试总分、Brooke评分、Vignos评分及CSS进行综合判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the clinical features of patients showing a classical phenotype of facioscapulohumeral muscular dystrophy (FSHD) with genetic and epigenetic characteristics of the FSHD1 and FSHD2 loci D4Z4 and SMCHD1. METHODS: This is a national multicenter cohort study. We measured motor strength, motor function, and disease severity by manual muscle testing sumscore, Brooke and Vignos scores, clinical severity score (CSS), and age-corrected CSS, respectively. We correlated these scores with genetic (D4Z4 repeat size and haplotype; SMCHD1 variant status) and epigenetic (D4Z4 methylation) parameters. RESULTS: We included 103 patients: 54 men and 49 women. Among them, we identified 64 patients with FSHD1 and 20 patients with FSHD2. Seven patients had genetic and epigenetic characteristics of FSHD1 and FSHD2, all carrying repeats of 9-10 D4Z4 repeat units (RU) and a pathogenic SMCHD1 variant. In the remaining patients, FSHD was genetically excluded or remained unconfirmed. All clinically affected SMCHD1 mutation carriers had a D4Z4 repeat of 9-16 RU on a disease permissive 4qA haplotype. These patients are significantly more severely affected by all clinical scales when compared to patients with FSHD1 with upper-sized FSHD1 alleles (8-10 RU). CONCLUSION: The overlap between FSHD1 and FSHD2 patients in the 9-10 D4Z4 RU range suggests that FSHD1 and FSHD2 form a disease continuum. The previously established repeat size threshold for FSHD1 (1-10 RU) and FSHD2 (11-20 RU) needs to be reconsidered. CLINICALTRIALSGOV IDENTIFIER: NCT01970735.
引用
- Sacconi S, Briand-Suleau A, Gros M, et al. FSHD1 and FSHD2 form a disease continuum. Neurology. 2019. PMID: 30979860. doi:10.1212/WNL.0000000000007456
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。